Clinical Trial Results:
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness
Summary
|
|
EudraCT number |
2017-000497-11 |
Trial protocol |
AT DE ES IT RO |
Global end of trial date |
01 Dec 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
03 Feb 2023
|
First version publication date |
03 Feb 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ALK3831-A307
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03187769 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Alkermes Inc
|
||
Sponsor organisation address |
852 Winter Street, Waltham, United States, MA 02451
|
||
Public contact |
Director, Corporate Communications, Alkermes Inc, mediainfo@alkermes.com
|
||
Scientific contact |
Sergey Yagoda MD PhD, Alkermes Inc, Sergey.Yagoda@alkermes.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Dec 2021
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Dec 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Dec 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the effect of ALKS 3831, compared to olanzapine, on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness
|
||
Protection of trial subjects |
A subject can be discontinued from the study at any time if the subject, Investigator, or Sponsor determined that it is not in the best interest of the subject to continue participation.
|
||
Background therapy |
Not applicable | ||
Evidence for comparator |
Olanzapine is recommended as a second-line treatment in patients early in illness according to the Schizophrenia Patient Outcomes Research Team (PORT) treatment guidelines | ||
Actual start date of recruitment |
22 May 2017
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
24 Months | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Israel: 32
|
||
Country: Number of subjects enrolled |
Ukraine: 77
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 2
|
||
Country: Number of subjects enrolled |
Russian Federation: 82
|
||
Country: Number of subjects enrolled |
United States: 206
|
||
Country: Number of subjects enrolled |
Poland: 2
|
||
Country: Number of subjects enrolled |
United Kingdom: 3
|
||
Country: Number of subjects enrolled |
Austria: 2
|
||
Country: Number of subjects enrolled |
Germany: 3
|
||
Country: Number of subjects enrolled |
Ireland: 4
|
||
Country: Number of subjects enrolled |
Italy: 13
|
||
Worldwide total number of subjects |
426
|
||
EEA total number of subjects |
24
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
7
|
||
Adults (18-64 years) |
419
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
Date of first subject's first visit was 08 June 2017. Date of last subject's last visit was 01 December 2021. The study included subjects from Austria, Germany, United Kingdom, Ireland, Israel, Italy, Poland, Russia, Ukraine, South Korea | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
A total of 640 subjects were screened. Subjects were screened at Visit 1, up to 30 days prior to randomization. At Visit 2, eligible subjects were randomized 1:1 to ALKS 3831 or Olanzapine and receive study drug for up to 12 weeks. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
Baseline (overall period)
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||||
Blinding implementation details |
A unique randomization number was assigned by an interactive web response system once eligibility was determined. Randomization codes were prepared by an independent biostatistician. The blind was maintained until the database lock on 03 January 2022
|
||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
ALKS 3831 | ||||||||||||||||||||||||||||||
Arm description |
ALKS 3831 | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
ALKS 3831
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
ALKS 3831 5/10mg, 10/10mg, 15/10mg or 20/10mg administered orally as a coated bilayer tablet. For the first week, at the discretion of the Investigator, subjects received 5/10mg, 10/10mg, 15/10mg or 20/10mg of ALKS 3831. At the end of Week 1, for subjects initiated on 5/10mg of ALKS 3831, the dose was increased to 10/10mg of ALKS 3831. For all other subjects, the dose was also increased to either 15/10mg or 20/10mg of ALKS 3831. Following this increase, the dose could be increased or decreased to 5/10mg, 10/10mg, 15/10mg or 20/10mg of ALKS 3831 at the Investigator's discretion.
|
||||||||||||||||||||||||||||||
Arm title
|
Olanzapine | ||||||||||||||||||||||||||||||
Arm description |
Olanzapine (OLZ) | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Olanzapine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
OLZ
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
Olanzapine 5mg, 10mg, 15mg or 20mg administered orally as a coated bilayer tablet. For the first week, at the discretion of the Investigator, subjects received 5mg, 10mg, 15mg or 20mg of olanzapine. At the end of Week 1, for subjects initiated on 5mg of olanzapine, the dose was increased to 10mg of olanzapine. For all other subjects, the dose was also increased to either 15mg or 20mg of olanzapine. Following this increase, the dose could be increased or decreased to 5mg, 10mg, 15mg or 20mg of olanzapine at the Investigator's discretion.
|
||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ALKS 3831
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
ALKS 3831 | ||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Olanzapine (OLZ) | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set ALKS 3831
|
||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Primary analysis: percent change from baseline in body weight at Week 12 (IM)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set OLZ
|
||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Full Analysis Set OLZ
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
ALKS 3831
|
||
Reporting group description |
ALKS 3831 | ||
Reporting group title |
Olanzapine
|
||
Reporting group description |
Olanzapine (OLZ) | ||
Subject analysis set title |
Full Analysis Set ALKS 3831
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Primary analysis: percent change from baseline in body weight at Week 12 (IM)
|
||
Subject analysis set title |
Full Analysis Set OLZ
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Full Analysis Set OLZ
|
|
||||||||||||||||
End point title |
Percent change from baseline in body weight at Week 12 | |||||||||||||||
End point description |
Percent change from baseline in body weight at Week 12
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
12 weeks
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
Percent Change from Baseline in Body Weight | |||||||||||||||
Statistical analysis description |
Primary efficacy: Percent Change from baseline in body weight at Week 12
|
|||||||||||||||
Comparison groups |
Full Analysis Set ALKS 3831 v Full Analysis Set OLZ
|
|||||||||||||||
Number of subjects included in analysis |
408
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
other [1] | |||||||||||||||
P-value |
= 0.012 [2] | |||||||||||||||
Method |
ANCOVA | |||||||||||||||
Confidence interval |
||||||||||||||||
level |
95% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
- | |||||||||||||||
upper limit |
- | |||||||||||||||
Notes [1] - Percentage change in weight gain when comparing ALKS 3831 to Olanzapine [2] - ALKS 3831 met the primary efficacy endpoint for percent change in body weight at Week 12, as the LS mean percent change from baseline was 4.91% for ALKS 3831 and 6.77% for Olanzapine (P=0.012) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Safety and tolerability analyses were performed using data from the safety population, defined as all subjects who received at least 1 dose of study drug.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety was evaluated based on the incidence of treatment-emergent adverse event (TEAEs), the incidence of SAEs and AEs leading to discontinuation, vital signs measurements, physical examination findings, body weight, laboratory test results, ECG findings, concomitant medications, and the Columbia-Suicide Severity Rating Scale (C-SSRS).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ALKS 3831
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
ALKS 3831 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Olanzapine (OLZ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 2% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
13 Mar 2017 |
The study protocol was amended to clarify that medication adherence and reminder system is not mandatory. To clarify special situations where hospital visits would be considered serious adverse events (SAEs), and update list of Cytochrome P450 (CYP) 3A4 inhibitors and inducers. |
||
10 May 2017 |
The study protocol was amended to incorporate site feedback regarding rater review for the MINI, to include that audio recording would be conducted during the MINI at the Screening Visit in order to ensure rater accuracy via central calibration/reading. Additionally, to specify that, in the US, previous antipsychotic exposure is required for paediatric subjects (greater than or equal to 16 years and less than 18 years of age) to qualify for participation in the study. To specify that clinically significant ECG abnormalities are exclusionary at Visit 1 only. To update the criteria for defining a serious adverse event (SAE). |
||
12 Sep 2017 |
The study protocol was amended to allow for the addition of a new exclusion criterion for subjects with known risk of narrow-angle glaucoma to align with olanzapine (OLZ) local labels, including the current Summary of Product Characteristics (SmPC). Additionally, to revise serum creatinine exclusion criterion, to revise inclusion criterion for antipsychotic treatment eligibility requirement, to revise exclusion criterion for suspected intolerance, allergy, or hypersensitivity to study drug to include any of the ingredients of the study drug. Further describe medications that exhibit drug interaction potential with OLZ, including detail on inhibitors and inducers of CYP 1A2 and of medicinal products known to increase QTc interval. |
||
10 Jan 2018 |
The study protocol was amended to update the inclusion and exclusion criteria, to add instructions for stoppage of treatment with mood stabilizers, to clarify use of a study-approved and calibrated scale for body composition analyzer measurements, to update the language regarding contraception requirements and to add additional randomization stratification factor. |
||
19 Jun 2019 |
The study protocol was amended to increase the sample size from 250 to 400 subjects in the efficacy population and remove the interim analysis. Approximately 425 subjects were proposed to be randomized to have 400 subjects in the efficacy population. To add additional secondary endpoints as follows: Change from baseline in waist circumference at Week 12, and change from baseline in CGI-S score within the ALKS 3831 Group at Week 12. Additionally, to make changes to other endpoints, revise methods for handling missing data and when multiple imputation (MI), summary statistics, or mixed model with repeated measurements (MMRM0 was performed. Changes were made to collection of data for randomized subjects who terminated the treatment early. Clarifications were made regarding subject eligibility (inclusion and exclusion criteria). The addition of Olanzapine (OLZ) starting dose 20 mg and ALKS 3831 starting dose of 20/10 mg during the first week of treatment. To clarify the requirements for selective serotonin reuptake inhibitor (SSRI) antidepressant use for subjects with schizophrenia and schizophreniform disorder. Addition of laboratory blood tests. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |